Recursion Pharmaceuticals announced a $200 million oversubscribed follow-on stock offering backed by major healthcare investors. The company reported promising Phase 1b/2 data for REC-4881 showing significant and durable reductions in precancerous polyps in Familial Adenomatous Polyposis (FAP) patients, including upper GI tract improvements. REC-1245 also showed encouraging early cancer responses. Additionally, Sanofi has optioned a first-in-class immunology candidate from their collaboration, triggering a $10 million milestone payment. The proceeds extend Recursion's cash runway into 2029, supporting ongoing clinical trials and pipeline advancement.
As of Oct 15, 2026 19:31 WIB, Recursion Pharmaceuticals (RXRX) trades at USD 3.41 on Pluang, down 8.82% for the day with a market cap of $2.02 billion. Meanwhile, Sanofi (SNY) is priced at USD 40.60, up 2.09%, with a market cap of $96.38 billion. Notably, Pluang order activity shows 73% selling interest in RXRX versus 100% buying interest in SNY, highlighting contrasting investor sentiment.
Recursion Pharmaceuticals announced that Sanofi has chosen their first development candidate from a joint immunology drug discovery collaboration, triggering a $10 million milestone payment to Recursion. This oral small molecule targets two inflammat...
Recursion Pharmaceuticals announced it priced an underwritten offering of 61.54 million Class A shares at $3.25 each, aiming to raise approximately $200 million before expenses. The funds will support its AI-enabled drug discovery platform and clinic...
